This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.



Drug Names(s): Zolpidem Tartrate, Stilnox (EU), Myslee (Japan)

Description: Ambien (zolpidem) is a short-acting hypnotic agent with a chemical structure unrelated to benzodiazepines. It binds, however, to the benzodiazepine receptor, which is the major modulatory site of the GABA-A receptor complex located on its alpha subunit. Zolpidem potentiates gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter. Subunit modulation of the GABA-A complex is thought to be responsible for sedative, anticonvulsant, anxiolytic, and myorelaxant drug properties.

Historical drug revenue includes Ambien and Ambien CR.

Deal Structure: In November 2007, sanofi-aventis and Astellas Pharma announced today that they have agreed to restructure their joint venture activities in Japan (FSA). Established in 1982, FSA is a joint venture company 51% owned by sanofi-aventis and 49% by Astellas. FSA owns the rights to manufacture and sell certain products originating from sanofi-aventis such as Ambien (Myslee in Japan). In the restructuring, sanofi-aventis K.K., the Japanese subsidiary of sanofi-aventis, shall obtain certain rights to Myslee. Myslee will continue to be co-promoted by sanofi-aventis K.K. and Astellas and distributed by Astellas.

Partners: Astellas Pharma, Inc.

Ambien News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug